Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Ch Kouroussis"'
Autor:
N, Karachaliou, Ch, Kouroussis, P, Papakotoulas, K, Kalbakis, K, Tryfonidis, N, Vardakis, E, Poppis, V, Georgoulias, D, Mavroudis
Publikováno v:
Cancer Chemotherapy and Pharmacology. 69:1345-1352
To evaluate the docetaxel-gemcitabine (DG) combination administered every 2 weeks as salvage therapy in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC).Thirty women with MBC who had disease progression after chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13d4e870d2feac70f5c8e6fc043ee0c0
https://doi.org/10.1007/s00280-012-1824-z
https://doi.org/10.1007/s00280-012-1824-z
Autor:
Sophia Agelaki, D. Mavroudis, Antonia Kalykaki, A. Kotsakis, Aristidis Polyzos, Ch. Kouroussis, L. Vamvakas, V. Georgoulias, N. Vardakis, Kostas Kalbakis, Nikos Androulakis
Publikováno v:
Oncology. 71:190-196
Purpose: A phase I study was conducted to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of the pegylated liposomal doxorubicin (PLD) and oxaliplatin combination in patients with advanced solid tumors. Patients and M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a150407b3e0e6d9857b84a42f3f4df5
https://doi.org/10.1159/000106068
https://doi.org/10.1159/000106068
Autor:
E Tselepatiotis, Ph. Palamidas, Ioannis Boukovinas, M. Veslemes, Ch. Kouroussis, Alexandros Ardavanis, M. Toubis, V. Georgoulias, Ioannis G. Vlachonikolis, E. Stavrinidis, Aristidis Polyzos, Kostas N. Syrigos, A Agelidou
Publikováno v:
British Journal of Cancer
To compare irinotecan (CPT-11)+gemcitabine vs CPT-11 alone as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC) progressing after docetaxel-cisplatinum-based therapy. A total of 147 evaluable, pretreated patients, wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d402a4f71ccfd6d51f13b0afec3b823
https://doi.org/10.1038/sj.bjc.6602010
https://doi.org/10.1038/sj.bjc.6602010
Autor:
Kostas Kalbakis, D. Mavroudis, Ch. Christophilakis, Ch. Kouroussis, N. Malamos, Nikos Androulakis, I. Varthalitis, V. Georgoulias, Aristidis Polyzos, G. Milaki
Publikováno v:
Oncology. 67:250-256
Objective: To evaluate the docetaxel-gemcitabine combination administered every 2 weeks in women with untreated metastatic breast cancer (MBC). Methods: Fifty-two patients with MBC received docetaxel 65 mg/m2 as front-line chemotherapy intravenously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e056520b8b601e0424c9cf12b00dcc3
https://doi.org/10.1159/000081325
https://doi.org/10.1159/000081325
Autor:
A. Alexopoulos, N. Malamos, Alexandros Ardavanis, Ch. Kouroussis, D. Mavroudis, V. Georgoulias, V. Bozionelou, Nikos Androulakis, C. Kandylis, Sophia Agelaki, E. Stavrinidis
Publikováno v:
Oncology. 64:207-212
Objectives: To evaluate the efficacy and safety of docetaxel in combination with carboplatin as salvage treatment in women with metastatic breast cancer (MBC). Patients and Methods: Chemotherapy-pretreated women with MBC were treated with docetaxel 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::317d9b6f8049c32eccbbf70afbe6797a
https://doi.org/10.1159/000069306
https://doi.org/10.1159/000069306
Autor:
D Mavroudis, M Veslemes, Ch Kouroussis, N Tzanakis, E Ferdoutsis, M Toumbis, P Ziotopoulos, M Agelidou, E Tselepatiotis, K Kalbakis, J Souglakos, E Magkanas, G Samonis, V Georgoulias, for the Hellenic Oncology Research Group
Publikováno v:
Lung Cancer. 38:59-63
Purpose: In order to investigate the feasibility of a potentially non-cross resistant drug regimen, we alternated cycles of cisplatin–etoposide with topotecan as front-line treatment in patients with extensive stage small cell lung cancer (SCLC). P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a3cecc1d8e37481f603e79135af0908
https://doi.org/10.1016/s0169-5002(02)00149-6
https://doi.org/10.1016/s0169-5002(02)00149-6
Autor:
John Souglakos, Sophia Agelaki, George Samonis, Ch. Kouroussis, S. Kakolyris, D. Mavroudis, Nikos Androulakis, Kostas Kalbakis, V. Georgoulias
Publikováno v:
Oncology. 62:216-222
Objectives: Paclitaxel and doxorubicin are among the most active chemotherapeutic agents in various types of tumors. Pegylated liposomal doxorubicin (Caelyx) has a more favorable pharmacokinetic and toxicity profile than the free drug. We conducted a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10efeb194edf885790cfd730dc6db7d4
https://doi.org/10.1159/000059568
https://doi.org/10.1159/000059568
Autor:
D. Mavroudis, C. Kosmas, S Papadouris, John Souglakos, Sophia Agelaki, V. Georgoulias, Kostas Kalbakis, Ch. Kouroussis, T. Giannakakis, N. Malamos
Publikováno v:
Oncology. 62:103-109
Aim: To define the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of the carboplatin-vinorelbine combination in pretreated patients with advanced breast cancer. Patients and Methods: Patients with histologically confirmed metast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01b0f231d4844f33da53c11cda6eb153
https://doi.org/10.1159/000048254
https://doi.org/10.1159/000048254
Autor:
Sophia Agelaki, John Souglakos, N. Vardakis, Ch. Kouroussis, Lambros Vamvakas, Kostas Kalbakis, V. Georgoulias, Stelios Kakolyris
Publikováno v:
Lung Cancer. 34:71-76
Irinotecan (CPT-11) and cisplatin (P) are both active agents against non-small cell lung cancer (NSCLC), and their combination has shown in vitro an additive or synergistic effect. We conducted a phase II study to determine the toxicity and efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ded54c20837d3dddcd95e091f2ee13df
https://doi.org/10.1016/s0169-5002(01)00384-1
https://doi.org/10.1016/s0169-5002(01)00384-1
Autor:
George Samonis, Th. Giannakakis, M. Veslemes, E. Papadakis, J. Vlachonikolis, V. Georgoulias, D. Mavroudis, Th. Grigoratou, S. Kakolyris, Ch. Kouroussis, Ageliki Rapti, Ph. Palamidas, A. Alexopoulos, X. Tsiafaki
Publikováno v:
Lung Cancer. 34:47-51
The study compares docetaxel plus cisplatin (DC) and docetaxel plus gemcitabine (DG) regimens for the treatment of advanced non-small cell lung cancer (NSCLC). Patients were randomized to receive either the DC or the DG combination. They were stratif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b6f16e5f160b7deed25fd5a94ae2e1c
https://doi.org/10.1016/s0169-5002(01)00417-2
https://doi.org/10.1016/s0169-5002(01)00417-2